Department of Health - Abu Dhabi, Boehringer Ingelheim ink strategic partnership
17 June 2025 13:56
ABU DHABI (WAM) The Department of Health - Abu Dhabi (DoH) signed a Memorandum of Understanding with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical companies.This strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development, and cultivate an environment of scientific excellence, further cementing the emirate as the MENA region's premier hub for healthcare, life sciences, and innovation.In the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI.Through this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim's OpnME platform.Researchers, scientists, and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery.Through four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks, and support for emerging talent.OpnME connects visionary researchers to champion transformative, research-driven medical innovation for generations to come.Al Mannaei said, 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as part of our efforts to advance health outcomes and improve the quality of life for communities around the world.We're empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.'
Alhaj said, 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration supports research, innovation, and the next generation of researchers in the region.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
5 hours ago
- Zawya
DoH and Boehringer Ingelheim Ink strategic partnership to advance life science innovation across the Emirate
Abu Dhabi, United Arab Emirates: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical companies. This strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development and cultivate an environment of scientific excellence, further cementing the Emirate as the MENA region's premier hub for healthcare, life sciences and innovation. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI. Through this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim'sOpnME platform. Researchers, scientists and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery. Through four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks and support for emerging talent. OpnME connects visionary researchers to champion transformative, research-driven medical innovation for generations to come. In line with Abu Dhabi's vision to shape the future of healthcare, this partnership between DoH and BI enhances knowledge exchange and invests in local talent. It offers scientists a purpose-driven, globally connected environment to lead impactful research, further reinforcing the Emirate's commitment to transforming the regional healthcare ecosystem through science and technology. Dr. Asma Ibrahim Al Mannaei, the Executive Director of the Health Life Sciences Sector at DoH, said: 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as parts of our efforts to advance health outcomes and improve the quality of life for communities around the world. We're empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.' Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said: 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration reflects our shared commitment to advancing research and innovation in the region, fostering a culture of discovery, and ultimately improving patient outcomes. By providing access to our scientific resources, including advanced compounds, collaborative research opportunities, and expert networks, we aim to inspire new ideas and support the next generation of researchers in Abu Dhabi.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 14 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
Al Etihad
8 hours ago
- Al Etihad
Department of Health - Abu Dhabi, Boehringer Ingelheim ink strategic partnership
17 June 2025 13:56 ABU DHABI (WAM) The Department of Health - Abu Dhabi (DoH) signed a Memorandum of Understanding with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development, and cultivate an environment of scientific excellence, further cementing the emirate as the MENA region's premier hub for healthcare, life sciences, and the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim's OpnME scientists, and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks, and support for emerging connects visionary researchers to champion transformative, research-driven medical innovation for generations to Mannaei said, 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as part of our efforts to advance health outcomes and improve the quality of life for communities around the empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.' Alhaj said, 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration supports research, innovation, and the next generation of researchers in the region.'
The National
8 hours ago
- The National
Abu Dhabi initiative raises Dh900m to assist patients with chronic diseases
An Abu Dhabi health drive has been hailed as a "pioneering" success after raising Dh900 million in only one month to support patients with chronicle illnesses, people with disabilities and senior citizens. The Life Endowment Campaign, established by the Endowments and Minors Funds Authority (Awqaf Abu Dhabi), was launched on May 19 to help meet the treatment costs of patients as part of a wider vision to make the health sector more sustainable. Organisers have praised the outpouring of support for the scheme, from both individuals and businesses, after more than 200,000 financial contributions were received. The humanitarian initiative, held under the slogan With you for Life, was announced by President Sheikh Mohamed under the UAE's Year of Community. Awqaf said it will continue to welcome donations to the flagship endowment campaign, which was established under the body's Healthcare Endowment initiative, launched in May, 2024 with the goal of raising Dh1 billion over five years. Investing in the emirate's health The funds raised are being used to create an endowment, which will serve to support treatment of patients and investment in services and medical supplies for years to come. An endowment fund acts as a philanthropic investment portfolio, with donations to used to establish an initial pool of money with the aim that this will be invested to grow in value. The Life Endowment will seek to maximise the returns of the endowment and direct them towards various healthcare programmes to improve quality of life of the public in the years ahead. Awqaf has announced a number of supporting endowment projects. These include the Awqaf Abu Dhabi - Community Centre project valued at Dh50 million, and a DhD70 million real estate endowment project in partnership with Aldar Properties. Key contributions to the campaign included a Dh172 million donation from Sheikha Fatima bint Mubarak, Mother of the Nation. Sheikh Theyab bin Mohamed, Deputy Chairman of the Presidential Court for Development and Fallen Heroes' Affairs and Chairman of the Board of Trustees of Erth Zayed Philanthropies, approved the allocation of Dh100 million from Erth Zayed Philanthropies to the campaign. This pledge was made under the directives of Sheikh Mansour bin Zayed, Vice President, Deputy Prime Minister and Chairman of the Presidential Court. 'The Life Endowment campaign has provided a pioneering model for transforming endowments into an innovative financial tool that allows for the efficient investment of endowment assets to generate sustainable returns that support key sectors and enhance the quality of life," said Abdulhamid Mohammed Saeed, chairman of Awqaf. "Exceeding its target by raising more than Dh900 million, the campaign demonstrates a growing public awareness of the endowment's power to drive positive social impact. 'The remarkable community engagement and generous contributions from individuals and organisations highlight the deeply ingrained culture of giving and social responsibility within the UAE.
